Fidra Therapeutics

United States

•Series A•Founded 2023•Updated 1 month ago

Bio Tech/Life SciencesB2C1-5 employees

Actively Raising

Immigrant Founder

About

Fidra Therapeutics is developing a novel antibody drug designed to clear extracellular inflammasome particles to prevent chronic inflammation, with the goal of treating neurodegenerative, cardiometabolic, and immunological diseases without broadly suppressing innate immunity.

Team

Harsh

Co-founder & CEO

Tim

Co-founder & Advisor

Products

FIT-035

Novel antibody drug targeting inflammasome particles to treat chronic inflammation driven diseases